UNCY FY2025 EPS Raised by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at Brookline Capital Management raised their FY2025 earnings per share (EPS) estimates for Unicycive Therapeutics in a research note issued to investors on Tuesday, April 1st. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings of ($0.04) per share for the year, up from their previous forecast of ($0.15). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ FY2025 earnings at ($0.04) EPS, FY2026 earnings at $1.52 EPS and FY2026 earnings at $1.52 EPS.

Separately, HC Wainwright increased their price target on shares of Unicycive Therapeutics from $4.00 to $7.50 and gave the company a “buy” rating in a research report on Tuesday, April 1st.

Unicycive Therapeutics Stock Down 12.6 %

Shares of UNCY stock opened at $0.52 on Friday. The firm has a market cap of $61.76 million, a price-to-earnings ratio of -0.53 and a beta of 2.15. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.45. The company’s 50 day moving average is $0.58 and its 200 day moving average is $0.57.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UNCY. XTX Topco Ltd acquired a new stake in Unicycive Therapeutics during the 3rd quarter worth $29,000. Virtu Financial LLC lifted its holdings in shares of Unicycive Therapeutics by 566.8% in the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock worth $30,000 after acquiring an additional 62,881 shares during the last quarter. Northern Trust Corp boosted its position in shares of Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock worth $46,000 after buying an additional 34,183 shares during the period. Geode Capital Management LLC grew its position in Unicycive Therapeutics by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock valued at $417,000 after acquiring an additional 122,089 shares in the last quarter. Finally, Acuta Capital Partners LLC increased its stake in Unicycive Therapeutics by 16.4% during the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company’s stock worth $1,829,000 after buying an additional 323,801 shares during the period. Hedge funds and other institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.